Listed and unlisted Adverse Events

Clinical research is always delayed. Why? Patient recruitment is cited as the reason across the industry. This partly happens because the efforts put forth by Sponsors & CROs are often put together with less than ideal effort and forethought. Many people in charge of trials are o ... Show More

Patient retention is a thing that often gets overlooked. Yet, it can be one of the largest reasons contributing to you losing patients in your trials, your practice and in your care. Luckily there are some quick and easy fixes Heather and I share. 

Being persuasive is important in any facet of life. Everyone has to “sell” something every day. This means selling why you should be selected for that promotion, why your kid should listen to you, or why you should go eat somewhere over another suggested place. This applies to cl ... Show More

Karen Andersen, biotechnology strategist for Morningstar Research Services, discusses what GLP-1 drugs’ demand means for the biopharma industry’s five-year outlook. And whether the weight-loss drugs pose a threat to snack food stocks.Why GLP-1 Drugs Are in Demand Competition Betw ... Show More

Why did news from a weight-loss drug pill trial boost Eli Lilly? And how are costs in the Medicare business affecting UnitedHealth? Plus, what ambitious goals has Netflix set for itself? Host Francesca Fontana discusses the biggest stock moves of the week and the news that drove ... Show More

Companies are spending big bucks advertising weight-loss drugs like Ozempic and Rybelsus. This week, we’re dropping an episode of Brian Goldman’s White Coat, Black Art podcast into our feed.We thought you might find the topic interesting. In Canada, "reminder ads" can only give t ... Show More

What did the inventor of the mRNA technology say about the mandating medicines and the political scapegoating of those who are hesitant against these mandates? What really happened at the public FDA hearing more than a week ago? Are the mandated stabs safe for us? What are some p ... Show More

What drove FuboTV’s gains? And how are bird-flu worries affecting vaccine makers? Plus, why did insurance shares drop? Host Francesca Fontana discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Learn more ... Show More

What’s driving big banks’ profit gains? And what was the result of the holiday season at Macy’s? Plus, what drove drops in some drugmakers’ shares? Host Francesca Fontana discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Market ... Show More

Novartis CEO Vas Narasimhan talks about transforming the pharmaceutical giant into an innovative medicines company. He speaks on "The David Rubenstein Show: Peer-to-Peer Conversations". This interview was recorded February 15 in New York.See omnystudio.com/listener for privacy in ... Show More

How did rivals help United take off? And what has investors worried about the health of CVS? Plus, why Netflix shares jumped. Host Francesca Fontana discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Lea ... Show More